Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupSarcomasDiseaseEwing SarcomaOsteosarcomaSubgroupICD10C40.-C41.-C41.9MeSHSarcoma, EwingSequenceEuro-B.O.S.S.: adjuvant (upfront tumor surgery), OsteosarcomaEuro-B.O.S.S.: neoadjuvant incl. postoperative therapy, OsteosarcomaChemotherapyChemo-substanceCabozantinibCisplatinDocetaxelDoxorubicinGemcitabineIfosfamideMethotrexateRegorafenibChemo-substanceCabozantinibCisplatinDocetaxelDoxorubicinGemcitabineIfosfamideMethotrexateRegorafenibChemo-substanceCabozantinibCisplatinDocetaxelDoxorubicinGemcitabineIfosfamideMethotrexateRegorafenibChemo-substanceCabozantinibCisplatinDocetaxelDoxorubicinGemcitabineIfosfamideMethotrexateRegorafenibNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%Folinic acidFosaprepitantFurosemideGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%Folinic acidFosaprepitantFurosemideGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%Folinic acidFosaprepitantFurosemideGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%Folinic acidFosaprepitantFurosemideGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateNo. Substances2358913Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksAllergic ReactionAnemia Hb below 8g/dlDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHand-Foot SyndromeHypertensionHypokalemiaHypophosphatemiaHypothyroidismIncrease AminotransferasesInfectionsLeukopeniaMucositisNephrotoxicityNeurotoxicityNeutropeniaOral MucositisPainProteinuriaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorDavis LEFerrari SItaliano AMarina NPalmeriniDiseaseHigh-grade Osteosarkom, Alter 41-65High-grade Osteosarkom, Alter 41-65, postoperativLokal fortgeschrittenes oder metastasiertes Osteosarkom, mind. 1 Vortherapie, ECOG 0-2Metastasiertes oder lokal fortgeschrittenes Osteosarkom / Ewing Sarkom, > 12 Jahre, ECOG 0-1Neu diagnostiziertes, resezierbares high-grade Osteosarkom, Alter bis 40, ECOG 0-2Rezidivierendes oder therapierefraktäres Osteosarkom, ECOG 0-2OriginIstituto Ortopedico Rizzoli, Bologna, ItalyKnight Cancer Institute, Oregon Health and Science University, PortlandOncology Department, Istituto Ortopedico Rizzoli, Bologna-Italy, EURO-B.O.S.S.Stanford University School of Medicine and Lucile Packard Childrens Hospital, CA, EURAMOS-1University of Bordeaux, Bordeaux, France, CABONE trialProtocols in Revision 8 protocols foundProtocols under revision.Cabozantinib 60, Osteosarcoma / Ewing Sarcoma (PID1869 V1.0)Cisplatin (50/50) / Doxorubicin 60, Osteosarcoma (PID1362 V2.2)Gemcitabine 900 / Docetaxel 75, Osteosarcoma (PID1935 V1.0)Ifosfamide 3 / Cisplatin (50/50), Osteosarcoma (PID1363 V2.1)Ifosfamide 3 / Doxorubicin 60, Osteosarcoma (PID1364 V2.0)MAP - Cisplatin 60 / Doxorubicin 37.5 / Methotrexate 12, Osteosarcoma (PID1346 V2.3)Methotrexate 8000, Osteosarcoma (PID1365 V1.3)Regorafenib 160, Osteosarcoma (PID1578 V1.0)
